July 26, 2014 2:38 PM ET


Company Overview of Elusys Therapeutics, Inc.

Company Overview

Elusys Therapeutics, Inc. operates as a biopharmaceutical company that develops antibody therapeutics for the treatment of life-threatening infectious disease. The company develops Anthim, a humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. Elusys Therapeutics, Inc. was formerly known as ErythroMed, Inc. The company was founded in 1998 and is based in Pine Brook, New Jersey.

25 Riverside Drive

Unit One

Pine Brook, NJ 07058

United States

Founded in 1998





Key Executives for Elusys Therapeutics, Inc.

Chief Executive Officer
Chief Financial Officer
Age: 63
Senior Director of Human Resources & Administration
Vice President of Corporate Development
Age: 52
Vice President of Development and Manufacturing
Compensation as of Fiscal Year 2014.

Elusys Therapeutics, Inc. Key Developments

Elysys Therapeutics, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 08:00 AM

Elysys Therapeutics, Inc. Presents at BioNJ CEO Summit 2013, Oct-04-2013 08:00 AM. Venue: Bridgewater Marriott, Bridgewater, New Jersey, United States. Speakers: Elizabeth Posillico, President and CEO.

Elusys Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM

Elusys Therapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Elusys Wins Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax

Elusys Therapeutics, Inc. announced that it has been awarded additional funding from the U.S. Government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack. The company has now received $149 million, under two advanced development contracts with a potential total value of $211 million, from the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. ETI-204 is an investigational anti-toxin and is a promising candidate for the treatment of inhalational anthrax in humans. The $14.5 million funding will be used to conduct final, expanded safety studies for intravenous (IV) administration of ETI-204, as well as a dose escalation safety study for intramuscular (IM) administration of the anti-toxin. IM administration would allow rapid administration of anti-toxin treatment to large numbers of people in an emergency setting. Elusys has also received funding previously from the U.S. Department of Defense to support the development of its IM formulation.

Similar Private Companies By Industry

Company Name Region
Mosaic Biosciences, Inc. United States
QiG Group, LLC United States
BioPharm Solutions, Inc. United States
OlFactor Laboratories, Inc. United States
RIT Oncology, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Elusys Therapeutics, Inc., please visit www.elusys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.